Loading market event…
Loading market event…
Worth noting Market event Sun, Nov 15 1 min read
Summit Therapeutics announced on November 15 that the US Food and Drug Administration had issued a complete response letter for ivonescimab, meaning the application cannot be approved in its current form. Summit sought approval to combine the drug with platinum-containing chemotherapy for non-small cell lung cancer that has spread nearby or elsewhere in the body, after treatment with drugs targeting EGFR, a protein that helps cancer cells grow.[1]
According to reports, the FDA found insufficient statistically significant evidence of an overall survival benefit—evidence that patients live longer. That objection came despite positive progression-free survival results, which measure how long patients remain alive without their cancer worsening.[2][3]
The decision prevents Summit from launching this treatment in the US under the submitted application, leaving potential sales for this use dependent on a future approval. The survival-evidence gap makes that timing harder to assess and leaves investors with less certainty about when the drug could generate revenue. A November 16 report put Summit’s share decline at 20%, reflecting the market’s repricing of the setback.[1][3]
For developers of competing cancer drugs, the case highlights the need to assess whether their trials can show longer survival and how long gathering that evidence could take. Here, delaying disease progression did not provide enough survival evidence for FDA approval; whether another program faces the same obstacle depends on its own data and proposed treatment use.[2][3]
Summit’s planned US launch for this lung-cancer use is blocked. Developers of competing treatments have reason to review the strength of their survival evidence: if they also need more data, revenue could be delayed while development spending continues. This decision alone does not establish that other drugs will be rejected.[1][2][3]